Cancer Patients Sought for Study
NCI researchers are enrolling participants, 6 years and older, with alveolar soft part sarcoma into a new research study testing whether an immunotherapy drug called atezolizumab is able to shrink the cancer. For more information, contact the Clinical Center Office of Patient Recruitment, 1-866-444-2214 (TTY 1-866-411-1010) or firstname.lastname@example.org. Read more online at https://go.usa.gov/xUA4s. Refer to study 17-C-0074.
Patients with Batten Disease Needed
Researchers are conducting a research study on CLN3, Batten disease—a neurodegenerative disease, with typical onset in children—to identify markers of disease and to better understand CLN3 and how it develops over time. If you have juvenile neuronal ceroid lipofuscinosis (CLN3, Batten disease), you may be eligible. Study-related tests and procedures are provided at no cost. For more information, call 1-866-444-2214 (TTY 1-866-411-1010). Read more at https://go.usa.gov/xnrrA. Refer to study 18-CH-0002.
NIAID Needs Healthy Vols
NIAID researchers seek healthy volunteers, 18-50 years old, for an investigational vaccine study targeting respiratory syncytial virus. Compensation is provided. For more information, call 1-866-833-5433 (TTY 1-866-411-1010). Email email@example.com or visit http://bit.ly/2nOkOvY.
Do You Have a Food Allergy?
NIAID researchers are seeking volunteers age 2 and older who have at least one food allergy to participate in a study to better understand how food allergies affect health. Participants receive a comprehensive nutritional evaluation and meet with a dietitian for individualized counseling. Compensation for participation is provided. For more information, contact the Clinical Center Office of Patient Recruitment at 1-866-444-2214 (TTY 1-866-411-1010) or email firstname.lastname@example.org. Read more at https://go.usa.gov/xQYw9. Refer to study 15-I-0162.
Patients with SMM Needed
NCI researchers are currently enrolling people with smoldering multiple myeloma (SMM) to test the combination of carfilzomib, lenalidomide and dexamethasone as to their safety and effectiveness in treating SMM. For information, call the Office of Patient Recruitment at 1-866-444-2214. Refer to study 12-C-0107. Read more online at https://go.usa.gov/xUy7r.